Jiangsu Hengrui Pharmaceuticals (01276) plans to adopt the H-share stock plan for 2026.
Hengrui Medicine (01276) announced that on August 19, 2026, the board of directors has decided to propose the adoption of the 2026 H Share Plan (2026H). The 2026 H Share Plan will take effect upon approval at the upcoming first extraordinary general meeting of shareholders () in 2026.
Jiangsu Hengrui Pharmaceuticals (01276) announced that on August 19, 2026, the Board of Directors has resolved to propose the adoption of the 2026 H Share Stock Plan (2026 H Share Stock Plan). The 2026 H Share Stock Plan will take effect after being approved at the upcoming first extraordinary general meeting of shareholders (Shareholders' Meeting) of the Company in 2026.
Related Articles
KINTOR PHARMA-B (09939) released its interim results, reporting a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%.
SICC Co., Ltd. (02631): It is estimated that the total impairment provision for the first half of 2026 will be 30.132 million yuan.
A-shares Evening Hotspots | Cancer Vaccine Achieves Milestone Breakthrough! Moderna Soared 150% at One Point, U.S. Pharmaceutical Stocks Explode Collectively
KINTOR PHARMA-B (09939) released its interim results, reporting a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%.
SICC Co., Ltd. (02631): It is estimated that the total impairment provision for the first half of 2026 will be 30.132 million yuan.
A-shares Evening Hotspots | Cancer Vaccine Achieves Milestone Breakthrough! Moderna Soared 150% at One Point, U.S. Pharmaceutical Stocks Explode Collectively
RECOMMEND
